The impact of 18F-Fluorodeoxyglucose Positron Emission Tomography (FDG-PET) on radiotherapy planning

Terapevticheskii Arkhiv

Volumn 73, Issue 10, 2001, Pages 11-14

  Dizendorf, E ^a   Baumert, B ^a   Von Schulthess, G K ^a   Luetolf, U M ^a   Steinert, H C ^a  

^a NONE

Author keywords

FDG PET; Oncology; Radiotherapy planning

Indexed keywords

FLUORODEOXYGLUCOSE F 18; RADIOPHARMACEUTICAL AGENT;

ADULT; ARTICLE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; FEMALE; HUMAN; MALE; METASTASIS; METHODOLOGY; NEOPLASM; PATHOLOGY; RADIOTHERAPY; RETROSPECTIVE STUDY; SCINTISCANNING;

ENGLISH ABSTRACT; FEMALE; FLUDEOXYGLUCOSE F 18; HUMAN; MALE; MIDDLE AGE; NEOPLASM METASTASIS; NEOPLASMS; RADIOPHARMACEUTICALS; RADIOTHERAPY; RETROSPECTIVE STUDIES; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0035232516     PISSN: 00403660     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Von Schulthess G. K., ed. Clinical positron emission tomography (PET): correlation with morphological cross-sectional imaging. Philadelphia: Lippincott; 1999.
2. Berlangieri S. U., Scott A. M., Knight S. R. et al. F-18 fluorodeoxyglucose positron emission tomography in the non-invasive staging of non-small cell lung cancer. Eur. J. Cardiothorac. Surg. 1999; 16 (suppl. 1): 25-30.
3. Gupta N. C., Graeber G. M., Bishop H. A. Comparative efficacy of positron emission tomography with fluorodeoxyglucose in evaluation of small (< 1 cm), intermediate (1 to 3 cm), and large (> 3 cm) lymph node lesions. Chest 2000; 117 (3): 773-778.
4. Weder W., Schmid R. A., Bruchhaus H. et al. Detection of extrathoracic metastases by positron emission tomography in lung cancer. Ann. Thorac. Surg. 1998; 66 (3): 886-892.
5. Stumpe K. D., Urbinelli M., Steinert H. C. et al. Whole-body positron emission tomography using fluorodeoxyglucose for staging of lymphoma: effectiveness and comparison with computed tomography. Eur. J. Nucl. Med. 1998; 25 (7): 721-728.
6. Steinert H. C., Huch Bom R. A., Buck A. et al. Malignant melanoma: staging with whole-body positron emission tomography and 2-[F-18]-fluoro-2-deoxy-D-glucose. Radiology 1995; 195 (3): 705-709.
7. Flamen P., Lerut A., Van Cutsem E. et al. Utility of positron emission tomography for the staging of patients with potentially operable esophageal carcinoma. J. Clin. Oncol. 2000; 18 (18): 3202-3210.
8. Lowe V. J., Kim H., Boyd J. H. et al. Primary and recurrent early stage laryngeal cancer: preliminary results of 2-[fluorine 18]fluoro-2-deoxy-D-glucose PET imaging. Radiology 1999; 212 (3): 799-802.
9. Bender H., Kirst J., Palmedo H. et al. Value of 18fluoro-deoxyglucose positron emission tomography in the staging of recurrent breast carcinoma. Anticancer Res. 1997; 17 (3B): 1687-1692.
10. 18F)FDG). Gynecol. Oncol. 1993; 51: 197-204.
11. Vanuytsel L. J., Vansteenkiste JK. F., Stroobants S. G. et al. The impact of (18)F-fluoro-2-dexy-D-glucose positron emission tomography (FDG-PET) lymph node staging on the radiation treatment volumes in patiens with non-small cell lung cancer. Radiother. Oncol. 2000; 55 (3): 317-324.
12. Nestle U., Walter K., Schmidt S. et al. 18F-deoxyglucose positron emission tomography (FDG-PET) for the planning of radiotherapy in lung cancer: high impact in patients with atelectasis. Int. J. Radiat. Oncol. Biol. Phys. 1999; 44 (3): 593-597.
13. Kiffer J. D., Berlangieri S. U., Scott A. M. et al. The contribution of 18F-fluoro-2-deoxyglucose positron emission tomographic imaging to radiotherapy planning in lung cancer. Lung Cancer 1998; 19(3): 167-177.
14. Munley M. T., Marks L. B., Scarfone C. et al. Multimodality nuclear medicine imaging in three-dimensional radiation treatment planning for lung cancer: challenges and prospects. Lung Cancer Ibid. 1999; 23 (2): 105-114.
15. Rahn A. N., Baum R. P., Adamietz I. A. et al. Value of 18F fluorodeoxyglucose positron emission tomography in radiotherapy planning of head-neck tumors. Strahlenther. Onkol. 1998; 174 (7): 358-364.